Piper Sandler analyst Biren Amin initiated coverage of Elevation Oncology with an Overweight rating and $10 price target. The company is developing EO-3021, for the treatment of gastric cancers and expects to provide a data update from the U.S. Phase 1 trial in mid-Q3, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELEV:
- Elevation Oncology initiated with an Overweight at Stephens
- 3 Best Stocks to Buy Now, 5/6/2024, According to Top Analysts
- Elevation Oncology files to sell 3.28M shares of common stock for holders
- Elevation Oncology files $350M mixed securities shelf
- Elevation Oncology reports Q1 EPS (23c), consensus (20c)